Dr. Eric Leuthardt, M.D.
Claim this profileWashington University School of Medicine
Studies Glioblastoma
Studies Cerebral Vasoconstriction Syndrome
8 reported clinical trials
16 drugs studied
Area of expertise
1Glioblastoma
Stage IV
IDH negative
germline
2Cerebral Vasoconstriction Syndrome
Affiliated Hospitals
Clinical Trials Eric Leuthardt, M.D. is currently running
Personalized DNA Vaccine + PD-1 Blockade
for Glioblastoma
This is a single institution, open-label, multi-arm, phase I study assessing the safety and immunogenicity of a personalized neoantigen-based personalized DNA vaccine combined with PD-1 blockade therapy in subjects with newly diagnosed, MGMT promoter unmethylated glioblastoma (GBM). Immune checkpoint blockade, specifically those targeting the PD-1/PD-L1 pathways, has shown efficacy in multiple solid and hematologic malignancies. Furthermore, as has been demonstrated in metastatic melanoma, combining PD-1/PD-L1 blockade with other immune checkpoint inhibitors has shown improved objective response rates, though there is a significant increase in serious immune-related adverse events. As such, current trials are exploring different doses, administration schedules, and immune checkpoint agents. One alternative approach, however, is to introduce a tumor-directed therapy such as a personalized neoantigen vaccine combined with these immune modulating agents (i.e. immune checkpoint blocking antibodies) to maximize the tumor-specific response but minimize the toxicity associated with increasing non-specific systemic immune activation by generating a potent and focused neoantigen specific immune response. This study will test the hypothesis that a personalized neoantigen DNA vaccine in combination with concurrent administration of immune checkpoint blockade therapy will enhance the magnitude and breadth of neoantigen-specific T cell responses while maintaining an acceptable safety profile. The overall goal of this study is to identify the optimal vaccine plus adjuvant platform that can be tested in a subsequent phase II study to determine the efficacy of a personalized neoantigen vaccine approach in patients with GBM.
Recruiting1 award Phase 1
Sonobiopsy
for Glioblastoma
This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. In addition to the standard diagnostics of anatomic imaging and surgical histology, sonobiopsy has the potential to become the third pillar for brain tumor management by radically advancing the ability to easily and regularly acquire tumor genetic and molecular signatures. This enhanced capability will have a dramatic impact on patient survival and quality of life.
Recruiting1 award N/A
More about Eric Leuthardt, M.D.
Clinical Trial Related2 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Eric Leuthardt, M.D. has experience with
- Auricular Vagus Nerve Stimulation
- Sham Auricular Vagus Nerve Stimulation
- Personalized Neoantigen DNA Vaccine
- Doxorubicin
- Etoposide
- MRI-guided Laser Ablation
Breakdown of trials Eric Leuthardt, M.D. has run
Glioblastoma
Cerebral Vasoconstriction Syndrome
Subarachnoid Hemorrhage
Protoplasmic Astrocytoma
Oligodendroblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Eric Leuthardt, M.D. specialize in?
Eric Leuthardt, M.D. focuses on Glioblastoma and Cerebral Vasoconstriction Syndrome. In particular, much of their work with Glioblastoma has involved Stage IV patients, or patients who are IDH negative.
Is Eric Leuthardt, M.D. currently recruiting for clinical trials?
Yes, Eric Leuthardt, M.D. is currently recruiting for 5 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Eric Leuthardt, M.D. has studied deeply?
Yes, Eric Leuthardt, M.D. has studied treatments such as Auricular Vagus Nerve Stimulation, Sham Auricular Vagus Nerve Stimulation, Personalized neoantigen DNA vaccine.
What is the best way to schedule an appointment with Eric Leuthardt, M.D.?
Apply for one of the trials that Eric Leuthardt, M.D. is conducting.
What is the office address of Eric Leuthardt, M.D.?
The office of Eric Leuthardt, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.